Erlotinib in previously treated non-small-cell lung cancer

Erlotinib in previously treated non-small-cell lung cancer

BACKGROUND: We conducted a randomized, placebo-controlled, double-blind trial to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line chemotherapy. METHODS: Patients with stage IIIB o...

Full description

Saved in:
Bibliographic Details
Main Authors: Frances A. Shepherd, José Rodrigues Pereira, Tudor Ciuleanu, Huat Tan Eng, Vera Hirsh, Sumitra Thongprasert, Daniel Campos, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, M. Van Kooten, Mircea Dediu, Brian Findlay, Dongsheng Tu, Dianne Johnston, Andrea Bezjak, Gary Clark, Pedro Santabárbara, Lesley Seymour
Format: Journal
Published: 2018
Subjects:
Medicine
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=22044445517&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/62363
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University

Internet

https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=22044445517&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/62363

Similar Items